A
Andreia Palmeira
Researcher at University of Porto
Publications - 58
Citations - 1608
Andreia Palmeira is an academic researcher from University of Porto. The author has contributed to research in topics: Docking (molecular) & Virtual screening. The author has an hindex of 20, co-authored 54 publications receiving 1256 citations. Previous affiliations of Andreia Palmeira include Institute of Molecular Pathology and Immunology of the University of Porto.
Papers
More filters
Journal ArticleDOI
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
TL;DR: New and innovative strategies, such as the fallback to natural products, the design of peptidomimetics and dual activity ligands emerged as a fourth generation of P-gp inhibitors, which failed to demonstrate an improvement in therapeutic efficacy.
Journal ArticleDOI
Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones.
Andreia Palmeira,M. Helena Vasconcelos,Ana C. R. Paiva,Miguel X. Fernandes,Madalena Pinto,Emília Sousa +5 more
TL;DR: The aminated thioxanthones represent a new class of P-gp inhibitors with improved efficacy in sensitizing a resistant P-glycoprotein overexpressing cell line (K562Dox) to doxorubicin.
Journal ArticleDOI
Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Agostinho Lemos,Mariana Leão,Joana Soares,Andreia Palmeira,Madalena Pinto,Lucília Saraiva,Maria Emília Sousa +6 more
TL;DR: The knowledge of structural requirements crucial to the development of small‐molecule inhibitors of the p53–MDM2/MDMX interactions has enabled the identification of novel antitumor agents with improved in vivo efficacy.
Journal ArticleDOI
New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors
Andreia Palmeira,Freddy Rodrigues,Emília Sousa,Madalena Pinto,M. Helena Vasconcelos,M. Helena Vasconcelos,Miguel X. Fernandes +6 more
TL;DR: Of the 21 hit compounds selected in silico, 12 were found to significantly increase the intracellular accumulation of Rhodamine‐123, a P‐gp substrate, which provides important clues for the non‐label use of known drugs as inhibitors of P‐ gp.
Journal ArticleDOI
Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
Mariana Leão,Clara Pereira,Alessandra Bisio,Yari Ciribilli,A. M. Paiva,Neuza Machado,Andreia Palmeira,Miguel X. Fernandes,Emília Sousa,Madalena Pinto,Alberto Inga,Lucília Saraiva +11 more
TL;DR: Besides its potential use as molecular probe and possible lead to develop anticancer agents, the pyranoxanthone 1 will pave the way for the structure-based design of a new class of p53-MDM2 inhibitors.